索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]袁蓉曼,邹新昌,张娜,等.非传统血脂指标与心血管疾病[J].国际心血管病杂志,2024,04:220-223.
点击复制

非传统血脂指标与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年04期
页码:
220-223
栏目:
综述
出版日期:
2024-07-31

文章信息/Info

Title:
-
作者:
袁蓉曼; 邹新昌; 张娜; 孙亚召; 刘东升; 孙培; 张书研
作者单位：067050 承德医学院研究生学院（袁蓉曼，张娜）；330008 南昌大学第二附属医院（邹新昌）；061002 沧州市人民医院心内科（孙亚召，刘东升，孙培，张书研）
Author(s):
-
关键词:
心血管疾病; 载脂蛋白B; 残余胆固醇; 氧化型低密度脂蛋白
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.04.008
文献标识码:
-
摘要:
血脂紊乱是心血管疾病（CVD）的重要危险因素，非传统血脂指标（如脂蛋白a、载脂蛋白B、非高密度脂蛋白胆固醇、残余胆固醇、氧化型低密度脂蛋白、小而密低密度脂蛋白）在CVD中有较好的预测价值。该文介绍非传统血脂指标与CVD的关系。
Abstract:
-

参考文献/References

[1] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study[J]. J Am Coll Cardiol, 2020, 76(25):2982-3021.
[2] White-Al Habeeb NMA, Higgins V, Wolska A, et al. The present and future of lipid testing in cardiovascular risk assessment[J]. Clin Chem, 2023, 69(5):456-469.
[3] 王安, 王治平, 宋丽华. 降低脂蛋白a水平的治疗进展[J]. 国际心血管病杂志, 2023, 50(3):151-154.
[4] Kosmas CE, Bousvarou MD, Papakonstantinou EJ, et al. Novel pharmacological therapies for the management of hyperlipoproteinemia(a)[J]. Int J Mol Sci, 2023, 24(17):13622.
[5] Farina JM, Pereyra M, Mahmoud AK, et al. Current management and future perspectives in the treatment of Lp(a) with a focus on the prevention of cardiovascular diseases[J]. Pharmaceuticals (Basel), 2023, 16(7):919.
[6] Wang SY, Zha L, Chen J, et al. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis[J]. Eur J Med Res, 2022, 27(1):211.
[7] Wang HP, Zhang N, Liu YJ, et al. Lipoprotein(a), family history of cardiovascular disease, and incidence of heart failure[J]. J Lipid Res, 2023, 64(7):100398.
[8] Pirillo A, Norata GD, Catapano AL. Beyond LDL-C levels, does remnant cholesterol estimation matter?[J]. Eur J Prev Cardiol, 2020, 27(10):1088-1090.
[9] Torzewski M. The initial human atherosclerotic lesion and lipoprotein modification-a deep connection[J]. Int J Mol Sci, 2021, 22(21):11488.
[10] Hao QY, Gao JW, Yuan ZM, et al. Remnant cholesterol and the risk of coronary artery calcium progression: insights from the CARDIA and MESA study[J]. Circ Cardiovasc Imaging, 2022, 15(7):e014116.
[11] Wadstr?m BN, Wulff AB, Pedersen KM, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study[J]. Eur Heart J, 2022, 43(34):3258-3269.
[12] Tada H, Kaneko H, Suzuki Y, et al. Association between remnant cholesterol and incident atherosclerotic cardiovascular disease, heart failure, and atrial fibrillation[J]. J Clin Lipidol, 2024, 18(1):3-10.
[13] 孙亚召, 白春兰, 吴英杰, 等. 残余胆固醇与早发心肌梗死及其临床结局的相关性[J]. 临床心血管病杂志, 2023, 39(8):618-623.
[14] Wang KX, Wang R, Yang JX, et al. Remnant cholesterol and atherosclerotic cardiovascular disease: metabolism, mechanism, evidence, and treatment[J]. Front Cardiovasc Med, 2022, 9:913869.
[15] 中国中西医结合学会检验医学专业委员会. 非传统血脂指标与动脉粥样硬化性心血管疾病风险管理中国专家共识[J]. 中华预防医学杂志, 2022, 56(4):405-421.
[16] Johannesen CDL, Mortensen MB, Langsted A, et al. ApoB and Non-HDL cholesterol versus LDL cholesterol for ischemic stroke risk[J]. Ann Neurol, 2022, 92(3):379-389.
[17] Ulloque-Badaracco JR, Al-kassab-Córdova A, Hernandez-Bustamante EA, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis[J]. Lipids Health Dis, 2023, 22(1):98.
[18] Langlois MR, Sniderman AD. Non-HDL cholesterol or apoB:which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?[J]. Curr Cardiol Rep, 2020, 22(8):67.
[19] 彭少怡, 苏国海. 载脂蛋白B预测心血管疾病风险的应用进展[J]. 国际心血管病杂志, 2023, 50(5):298-301.
[20] Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook[J]. Atherosclerosis, 2023, 383:117312.
[21] Agongo G, Raal F, Nonterah EA, et al. Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: analysis of an array of lipid metrics in an AWI-Gen sub-study[J]. PLoS One, 2022, 17(12):e0278375.
[22] Qiao YN, Zou YL, Guo SD. Low-density lipoprotein particles in atherosclerosis[J]. Front Physiol, 2022, 13:931931.
[23] Khatana C, Saini NK, Chakrabarti S, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis[J]. Oxid Med Cell Longev, 2020, 2020:5245308.
[24] Doll J, Bürkle F, Neide A, et al. Contrast-enhanced ultrasound for determining muscular perfusion after oral intake of L-citrulline, L-arginine, and galloylated epicatechines: a study protocol[J]. Medicine (Baltimore), 2020, 99(41):e22318.
[25] Rodríguez-Sánchez E, Navarro-García JA, González-Lafuente L, et al. Oxidized low-density lipoprotein associates with ventricular stress in young adults and triggers intracellular Ca2+ alterations in adult ventricular cardiomyocytes[J]. Antioxidants (Basel), 2020, 9(12):1213.
[26] Hong CG, Florida E, Li HO, et al. Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: a systematic review and meta-analysis[J]. Front Cardiovasc Med, 2023, 9:1023651.
[27] Sheikh MSA. Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 acts as a new biomarker for NSTEMI and STEMI patients[J]. Afr Health Sci, 2022, 22(3):349-358.
[28] Sekimoto T, Koba S, Mori H, et al. Small dense low-density lipoprotein cholesterol: a residual risk for rapid progression of non-culprit coronary lesion in patients with acute coronary syndrome[J]. J Atheroscler Thromb, 2021, 28(11):1161-1174.
[29] Jiang H, Zhou YW, Nabavi SM, et al. Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis[J]. Front Cardiovasc Med, 2022, 9:925923.
[30] Jin X, Yang S, Lu J, et al. Small, dense low-density lipoprotein-cholesterol and atherosclerosis: relationship and therapeutic strategies[J]. Front Cardiovasc Med, 2022, 8:804214.
[31] Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(11):e0241993.
[32] Tanaka M, Sato T, Endo K, et al. An increase in calculated small dense low-density lipoprotein cholesterol predicts new onset of hypertension in a Japanese cohort[J]. Hypertens Res, 2023, 46(12):2635-2645.
[33] Inyaku M, Tanaka M, Sato T, et al. Calculated small dense low-density lipoprotein cholesterol level is a predominant predictor for new onset of ischemic heart disease[J]. J Atheroscler Thromb, 2024, 31(3):232-248.

备注/Memo

备注/Memo:
通信作者：刘东升， E-mail：1l9d8s3@163.com
更新日期/Last Update: 2024-07-31